Show simple item record

dc.contributor.authorMoyle, Peter M
dc.contributor.authorHartas, Jon
dc.contributor.authorHenningham, Anna
dc.contributor.authorBatzloff, Michael R
dc.contributor.authorGood, Michael F
dc.contributor.authorToth, Istvan
dc.date.accessioned2018-07-30T01:30:27Z
dc.date.available2018-07-30T01:30:27Z
dc.date.issued2013
dc.date.modified2014-01-30T22:52:29Z
dc.identifier.issn1549-9634
dc.identifier.doi10.1016/j.nano.2013.01.009
dc.identifier.urihttp://hdl.handle.net/10072/56283
dc.description.abstractA novel vaccine development platform that enables the site-specific conjugation of synthetic lipid adjuvants to recombinant proteins was produced. This technology facilitates the simple and efficient production of homogeneous, chemically-defined, semisynthetic lipoprotein vaccines. Using a polytope 'string-of-beads' approach, a synthetic gene incorporating seven Streptococcus pyogenes M protein strain-specific antigens, and a conserved M protein antigen (J14) was produced, expressed, and attached to a lipoamino acid based adjuvant (lipid core peptide; LCP). Nanoparticles (40 nm diameter) of an optimal size for stimulating antibody-mediated immunity were formed upon the addition of these lipoproteins to aqueous buffer (PBS). Systemic antigen-specific IgG antibodies were raised against all eight antigens in C57BL/6 J mice, without the need to formulate with additional adjuvant. These antibodies bound cell surface M proteins of S. pyogenes strains represented within the polytope sequence, with higher antibody levels observed where a dendritic cell targeting peptide (DCpep) was incorporated within the LCP adjuvant.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.language.isoeng
dc.publisherElsevier
dc.publisher.placeUnited States
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom935
dc.relation.ispartofpageto944
dc.relation.ispartofissue7
dc.relation.ispartofjournalNanomedicine: Nanotechnology, Biology and Medicine
dc.relation.ispartofvolume9
dc.rights.retentionY
dc.subject.fieldofresearchBacteriology
dc.subject.fieldofresearchApplied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
dc.subject.fieldofresearchChemical Sciences
dc.subject.fieldofresearchBiological Sciences
dc.subject.fieldofresearchTechnology
dc.subject.fieldofresearchcode060501
dc.subject.fieldofresearchcode110702
dc.subject.fieldofresearchcode03
dc.subject.fieldofresearchcode06
dc.subject.fieldofresearchcode10
dc.titleAn efficient, chemically-defined semisynthetic lipid-adjuvanted nanoparticulate vaccine development system
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2013 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.
gro.date.issued2013
gro.hasfulltextFull Text
gro.griffith.authorBatzloff, Michael R.
gro.griffith.authorGood, Michael F.
gro.griffith.authorHartas, Jon C.


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record